Cenegermin
Also known as: Cenegermin, NGF eye drops, Oxervate, recombinant human nerve growth factor, rhNGF
Source Cenegermin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Cenegermin (Oxervate) is a recombinant human nerve growth factor formulated as ophthalmic eye drops for the treatment of moderate to severe neurotrophic keratitis.
Mechanism of Action
Binds TrkA and p75NTR receptors on corneal epithelial cells, promoting survival, proliferation, and differentiation to facilitate corneal healing.
Routes of Administration
Goals & Uses
- Neurotrophic keratitisOphthalmologyHigh
- Healing of neurotrophic keratitis corneal ulcers/epithelial defectsTherapeuticHigh
- Restoration of corneal sensitivityTherapeuticModerate
- Corneal nerve regenerationTherapeuticModerate
- Prevention of disease progression to corneal perforationTherapeuticModerate
Contraindications
- Active ocular or periocular infection not adequately treatedInfectiousModerate
- Hypersensitivity to cenegermin or any excipientAllergic/ImmunologicHigh
Adverse Effects
- Increased intraocular pressureOcularRare
- Increased lacrimationOcularCommon
- Foreign body sensationOcularCommon
- Conjunctival hyperemiaOcularCommon
- Ocular painOcularCommon
- Ocular hyperemia (conjunctival redness)OcularCommon
- Corneal depositsOcularCommon
- Ocular inflammationOcularUncommon
- Eye painOcularCommon
Drug Interactions
- Benzalkonium chloride-containing eye dropsModerate
- Other ophthalmic solutionsLow
- Other ophthalmic medicationsLow
Population Constraints
- Pediatric patients (under 18 years)AgeRelative
- Pediatric patients (<1 year)AgeRelative
- Contact lens wearersDevice InteractionRelative
- Pregnant or breastfeeding womenReproductiveRelative
Regulatory Status
- European UnionApprovedApproved: Neurotrophic keratitisMarketed as Oxervate.
- United StatesInvestigationalUnder FDA review; not yet approved.
- United KingdomApprovedApproved: Neurotrophic keratitisFollows EMA approval.
Approved by the EMA in 2017 and the FDA in 2018 for moderate to severe neurotrophic keratitis. Designated as an orphan drug in both the EU and US given the rarity of the condition.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Cenegermin?
Cenegermin (Oxervate) is a recombinant human nerve growth factor formulated as ophthalmic eye drops for the treatment of moderate to severe neurotrophic keratitis.
What is Cenegermin used for?
Cenegermin is educationally associated with: Neurotrophic keratitis, Healing of neurotrophic keratitis corneal ulcers/epithelial defects, Restoration of corneal sensitivity, Corneal nerve regeneration, Prevention of disease progression to corneal perforation. Educational only — not medical advice.
How is Cenegermin administered?
Recorded routes of administration: Ophthalmic (eye Drops), Topical Ocular.
What are the potential side effects of Cenegermin?
Reported adverse effects include: Increased intraocular pressure, Increased lacrimation, Foreign body sensation, Conjunctival hyperemia, Ocular pain, Ocular hyperemia (conjunctival redness), Corneal deposits, Ocular inflammation, Eye pain. This list is not exhaustive — consult a qualified clinician.
Who should avoid Cenegermin?
Recorded contraindications: Active ocular or periocular infection not adequately treated, Hypersensitivity to cenegermin or any excipient. Consult a qualified clinician before use.